Despite our efforts to include all relevant studies, it is possible that some important studies were overlooked or excluded due to our search criteria or other limitations
Specifically, our claims data show a GMC of approximately $230 based on 410,021 single frequency claims for CPT code 93880, which is consistent with the GMC of approximately $246 for APC 5523, rather than the GMC of approximately $563 for APC 5524 (Level 4 Imaging without Contrast)
Medicare Part D claims for Ozempic, Rybelsus, Trulicity, and Mounjaro increased from 1.4 million in 2018 to 8.7 million in 2022 (Figure 1)
Tirzepatide (MD: 10 kg, 95%CI: 12, 8.2), semaglutide (MD: 3.8 kg, 95%CI: 4.9, 2.7), EBID (MD: 2.8 kg, 95%CI: 4.2, 1.4), liraglutide (MD: 2.1 kg, 95%CI: 3.2, 1.1), lixisenatide (MD: 2.0 kg, 95%CI: 3.3, 0.75) and dulaglutide (MD: 1.2 kg, 95%CI: 2.1, 0.25) showed statistically significant reduction in weight from baseline in comparison to traditional antidiabetic drugs (S8 Fig)